[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stillbirth\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stillbirth":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,55,87,116,141,167,216,242,285,307,341,364],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100637506","feasibility-trial-of-the-womb-watch-smartphone-app-to-assess-fetal-movements-100637506",false,"NCT07626112","Feasibility Trial of the Womb Watch Smartphone App To Assess Fetal Movements","A Pilot Study of the Womb Watch App: Fetal Assessment Using the Microphone of the Smartphone","WWA","Inclusion Criteria:\n\n* Ability to understand and voluntarily provide written signed informed consent to participate in the study.\n* English speaking (the alpha version of the Womb Watch app is only available in English)\n* Singleton intrauterine pregnancy\n* Estimated gestational age at enrollment 28 weeks to 32 weeks\n* Low-risk pregnancy with normal fetal growth and anatomy and no maternal co-morbidities of note.\n* High-risk pregnancy including fetal anomalies and maternal co-morbidities including but not limited to cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine\u002Fmetabolic, immunologic, dermatologic, neurologic, or oncologic.\n* No prior diagnosis of an anxiety mood disorder or a psychiatric illness\n* Access to internet\n* A functioning email address\n* Owns personal smartphone; iPhone or Android of any generation\n\nExclusion Criteria:\n\n* Currently pregnant with multiples (twins or more)\n* Baseline GAD-7 score of 10 or more","FEMALE","18 Years","45 Years",{"count":21,"type":22},60,"ESTIMATED","OBSERVATIONAL","The surveillance of pregnancies at risk for fetal loss secondary to high-risk maternal or fetal conditions remains a mainstay of perinatal care. Current testing to prevent fetal loss includes the regular use of ultrasound (biophysical profile) or fetal heart rate monitoring (non-stress test) in an outpatient clinic setting once or twice weekly. A patient may also be asked to subjectively assess daily fetal movements during the time between routine antepartum testing appointments. However, there are no good systems for pregnant women to objectively measure fetal movements. Smartphones have allowed for the development of applications that utilize various embedded devices including the camera and microphone.\n\nIn our recent pilot STUDY00001552 of 205 pregnant patients, placement of the iPhone10 microphone directly on the maternal abdominal wall was utilized to detect fetal movements. AI assessment of the audio recordings proved superior to maternal perception of fetal movements that were recorded during simultaneous ultrasound (gross fetal movements: 64% audio vs 18% maternal; breathing: 93% vs 3%, hiccups: 73% vs 3%).\n\nThis trial is a prospective, observational, feasibility study of 60 patients that includes both low-risk and high-risk pregnant women to examine the usability of the Womb Watch smartphone application.\n\nThe study will involve introduction of the Womb Watch app to a population of pregnant patients. Features of the app will be modified based on participant feedback. Anxiety levels of the patient will be tracked serially using a survey tool. The various types and versions of smartphones will be assessed to see if they affect the AI model. Finally, patients will be asked to determine the strength of fetal movements to see if this parameter can be assessed by the AI model. Amniotic fluid data will assessed through clinical ultrasounds to see if this also has any effect on the AI model's ability to detect fetal movements.",[26,27,28,29,30,31,32],"Assessment of Fetal Movement","Pregnancy","Pregnancy Complications","Pregnancy Complications Affecting Fetus (Diagnosis)","Stillbirth","Stillbirth and Neonatal Mortality","Fetal Movement",[34,35,36,37,38,39,40,41],"fetal movement","stillbirth","pregnancy","decreased fetal movement","IUFD","fetal demise","fetal kick counting","antenatal testing","NOT_YET_RECRUITING","2026-05-30",{"date":45,"type":46},"2026-06-04","ACTUAL",{"date":48,"type":22},"2026-07-01",{"date":50,"type":22},"2027-09-30",{"name":52,"class":53},"Kenneth Moise MD","OTHER",3,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100634300","phase-2-perioperative-dexmedetomidine-to-reduce-post-procedure-grief-following-second-trimester-dilation-and-evacuation-100634300","NCT07537894","Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation","Inclusion Criteria:\n\n* English- or Spanish-fluency\n* 16-26 weeks gestation\n* D\\&E in the operating room\n\nExclusion Criteria:\n\n* Unscheduled or emergent procedure\n* Contraindication to dexmedetomidine per package insert\n* Judgement of clinical anesthesiologist providing care",{"count":62,"type":22},100,"INTERVENTIONAL",[65,66],"PHASE2","PHASE3","People seeking second-trimester dilation and evacuation (D\\&E) procedures are often facing profoundly challenging circumstances, including desired pregnancies complicated by fetal anomalies or demise, serious maternal health conditions, or changes in financial or relationship status. Although abortion regret is uncommon, the emotional burden surrounding these experiences is substantial: many patients experience significant grief and post-traumatic stress symptoms in the weeks to months following care. Perioperative interventions that decrease the body's stress response offer a promising opportunity to reduce downstream psychologic morbidity. Dexmedetomidine has been shown to reduce PTSD symptoms in other high-stress medical and surgical settings. The investigators are undertaking a randomized trial to evaluate whether perioperative administration of dexmedetomidine during second-trimester D\\&E can reduce the frequency and severity of post-procedural grief, directly addressing an unmet need in patient-centered, trauma-informed abortion care.",[69,30,70,71],"Abortion","PTSD (Childbirth-Related)","Grief (Traumatic Grief and Existential Grief)",[73,74,39,35,75,76],"abortion","dexmedetomidine","grief","PTSD","2026-04-10",{"date":79,"type":46},"2026-04-17",{"date":81,"type":22},"2026-07",{"date":83,"type":22},"2028-07",{"name":85,"class":53},"Stanford University",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":63,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100630983","a-feasibility-randomised-control-trial-to-evaluate-early-perinatal-bereavement-counselling-for-parents-who-have-experienced-a-perinatal-death-100630983","NCT07494760","A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experienced a Perinatal Death","Perinatal Loss - Early Referral for Counselling (PEARL-C): A Feasibility Randomised Controlled Trial","PEARL-C","Inclusion Criteria:\n\n* Women and partners of women who have had a late fetal loss (from 16 weeks), stillbirth or neonatal death within the maternity unit at Wythenshawe Hospital.\n* For the qualitative interviews, healthcare professionals who have been involved with referrals to the intervention and\u002For the delivery of the intervention\n\nExclusion Criteria:\n\n* Less than 16 years of age\n* Anyone who lacks the capacity to consent\n* Inability to read English (interpreters will be provided for counselling sessions and interviews if needed).",true,"ALL","16 Years",{"count":99,"type":22},26,[101],"NA","The goal of this feasibility randomised control trial is to determine if a trial to evaluate perinatal bereavement counselling for parents who have experienced a perinatal death is feasible. The main question it aims to answer is:\n\n• Is a trial to evaluate access to perinatal bereavement counselling feasible?\n\nResearchers will compare the intervention group (parents who have received counselling) to the control group (parents who have not received counselling) to see if there are differences in measurements of parents' grief and psychological symptoms.\n\n* Participants allocated to the intervention and control group will receive usual bereavement care from the perinatal bereavement team at the hospital\n* Parents allocated to the intervention group will receive counselling\n* Parents will complete validated psychometric questionnaires about their levels of perinatal grief, psychological distress, depression, and quality of life\n* Parents in the intervention group will be asked a series of open-ended written questions about their experience of participating in the trial\n* Healthcare professionals who have been involved with delivery of the intervention\u002Freferrals will be interviewed about their experience of the trial.",[30,104,105,106],"Perinatal Death","Psychological","Grief","2026-03-20",{"date":109,"type":46},"2026-03-27",{"date":111,"type":22},"2026-03-01",{"date":113,"type":22},"2027-09-01",{"name":115,"class":53},"University of Manchester",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":86},"100392687","the-tommys-national-rainbow-clinic-study-100392687","NCT04393259","The Tommy's National Rainbow Clinic Study","The Tommy's National Rainbow Clinic Study: Evaluation of a Specialist Antenatal Service for Women and Families Following a Stillbirth or Neonatal Death","Inclusion Criteria:\n\n* Women who are attending the Rainbow Clinic because they have had prior stillbirth, neonatal death or late termination of pregnancy\n* Women who are currently pregnant\n\nExclusion Criteria:\n\n* Less than 16 years of age\n* Anyone who lacks capacity to consent","50 Years",{"count":125,"type":22},500,"The death of a baby before or shortly after birth affects approximately 1 in every 250 pregnancies in the UK meaning that over 4,000 parents experience the death of a baby each year in the UK. The majority of women who have experienced the loss of a baby will have another pregnancy, usually within a year.\n\nOur analysis of 14 studies concluded that parents need specialist support from doctors and midwives in a future pregnancy to reduce the risk of pregnancy complications and to provide the care and support they need. The Rainbow Clinic model aims to provide specialist care and support to families who have experienced the death of a baby during pregnancy or shortly afterwards. Rainbow Clinic was initially established in St Mary's Hospital, Manchester in 2013.\n\nThe Rainbow Clinic team are now working to establish Rainbow Clinics in other maternity units throughout the UK. As this is a new clinical service the investigators would like to evaluate the care provided in the Rainbow clinics across the United Kingdom, to look at women's experiences of care, their levels of anxiety and depression, to identify where care can be improved and the pregnancy outcomes of women attending Rainbow Clinic. This evaluation needs information about pregnancy outcomes and women's experiences. Participation in this research study will allow us to collect and aggregate this information. The investigators will ask all women attending participating Rainbow Clinics to complete a short questionnaire early in their pregnancy and again at the end. The study will collect information about the outcome of their pregnancy.",[30],[129,130,131,132],"Pregnancy after loss","Antenatal care","Anxiety","Depression","RECRUITING","2026-03-12",{"date":136,"type":46},"2026-03-16",{"date":138,"type":46},"2020-12-01",{"date":50,"type":22},{"name":115,"class":53},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":95,"sex":96,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":63,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":86},"100593861","walk-with-me-wwm-for-perinatal-grief-100593861","NCT07011940","Walk With Me (WWM) for Perinatal Grief","PeriGrief-II","Inclusion Criteria:\n\n* Within the first month of pregnancy or early infant loss\n* Reside in the United State\n* Speak and read either English or Spanish at a 6th grade reading level\n* 15 or older\n\nExclusion Criteria:\n\n* Not pregnant or has not experienced an early infant loss\n* Does not reside in the United State\n* Does not speak and read either English or Spanish at a 6th grade reading level\n* 14 or younger","15 Years",{"count":150,"type":22},300,[101],"The goal of this clinical trial is to learn if the Along With Me web-based intervention works to decrease posttraumatic stress symptoms and suicidal ideation among bereaved parents following pregnancy and early infant loss. It will also learn whether peer guides provide additional improvements on these outcomes.\n\nThe main questions it aims to answer are:\n\n• Do people who receive Along With Me or Along With Me plus a Peer Guide compared to services as usual have lower posttraumatic stress symptoms and suicidal ideation than those who do not receive the intervention?\n\nResearchers will compare Along With Me and Along With Me plus a Peer Guide to services as usual (referrals made in the hospital setting) to see if Along With Me works to prevent and address posttraumatic stress symptoms and suicidal ideation.\n\nParticipants will:\n\n* Receive access to a mobile app with approximately 10 therapeutic modules about how to manage grief and other symptoms.\n* Receive check-ins with a Peer Guide (in the Peer Guide condition only)",[106,154,155,156,30,157],"Post Traumatic Stress Disorder","Suicidal Ideation","Miscarriage","Infant Death","2026-03-04",{"date":160,"type":46},"2026-03-06",{"date":48,"type":22},{"date":163,"type":22},"2027-08-31",{"name":165,"class":166},"Oregon Research Behavioral Intervention Strategies, Inc.","INDUSTRY",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":176,"conditions":177,"keywords":196,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100345304","fetal-electrophysiologic-abnormalities-in-high-risk-pregnancies-associated-with-fetal-demise-100345304","NCT03775954","Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise","Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise","Inclusion Criteria:\n\n* Current pregnancy complicated by one of the five diagnostic categories\n\n  * prior unexplained Stillbirth at\u002Fafter 20 weeks gestation\n  * fetal major congenital heart defect\n  * fetal hydrops\n  * fetal gastroschisis\n  * monochorionic twin pregnancy\n* Subject must be 18 years of age or older\n* Subject must be English speaking and must be able to read and sign the consent form in English\n* Subject must be able to recline comfortably for 1-3 hours\n* Subject must be willing to complete all three procedures (fMCG, fMCG, nECG) as per protocol, unless medically unable\n* Subject must be willing to allow us to review her and her infants prenatal, deliver, and post-natal records to verify diagnosis, and clinical findings.\n\nExclusion Criteria:\n\n* Severe claustrophobia not reduced by taking breaks, or by having the light on, or by having someone in the room with them.\n* Active labor\n* Acute illness\n* Unable to recline comfortably with a pillow for more than 1-3 hours (assuming some breaks are provided)\n* Weight over 450 lbs\n* An electric stimulation device (TENS unit, pacemaker, or nerve stimulator) that could produce electric or magnetic noise.\n\n  * Note that the Tristan 624 Magnetometer does not pose a risk to the subject's device, (since fMCG does not produce any energy or magnetism), but stimulators themselves can cause interference for our recordings. Some devices may still qualify, and discussion with study nurse may be useful if subject has a pacemaker or similar device.\n\nThe subject will have a single 2-3 hour fetal magnetocardiogram at approximately 20 and 27 weeks GA, and again, if medical condition allows, between 30 and 37 weeks GA, then her infant will have an ECG between 0 and 4 weeks of age. Subjects will be paid a nominal fee for their participation each time, as well as transportation reimbursement if \\>25 miles. For subjects traveling a long distance, the ECG may be performed locally or at home.",{"count":175,"type":22},30,"Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden electrophysiologic abnormalities that could lead to fetal demise in five high-risk pregnancy conditions associated with fetal demise.",[178,179,180,181,182,183,30,184,185,186,187,188,189,190,191,192,193,194,195],"High Risk Pregnancy","Congenital Heart Disease","Fetal Hydrops","Twin Monochorionic Monoamniotic Placenta","Gastroschisis","Fetal Demise","Fetal Arrhythmia","Long QT Syndrome","Intrauterine Fetal Death","Sudden Infant Death","Pregnancy Loss","Twin Twin Transfusion Syndrome","Birth Defect","Fetal Cardiac Anomaly","Fetal Cardiac Disorder","Fetal Death","Brugada Syndrome","Fetal Tachycardia",[197,30,198,199,200,178,27,201,202,203,204,205,206],"Fetal Magnetocardiography","Intrauterine Fetal Demise","Fetal Heart Rate Variability","Fetal Arrhythmias","Fetal Anomaly","Fetal Echocardiography","Non-Stress Testing","New Technology","Birth Defects","Fetal Research","2026-03-02",{"date":158,"type":46},{"date":210,"type":46},"2018-07-01",{"date":212,"type":22},"2028-11-30",{"name":214,"class":53},"Medical College of Wisconsin",2,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":95,"sex":17,"minAge":97,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":86},"100336573","investigating-the-structured-use-of-ultrasound-scanning-for-fetal-growth-100336573","NCT03662178","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth (Oxford Growth Restriction Identification Programme (OxGRIP)) on Risk Factors for and the Incidences of Adverse Maternal, Fetal and Neonatal Outcome","OxGRIP","Inclusion Criteria:\n\n• All pregnant women receiving antenatal care at the Oxford University Hospitals NHS Foundation Trust (OUHFT) from January 2013 to 31st December 2019 with no exclusion criteria\n\nExclusion Criteria:\n\n* Women who have opted out of research related to pregnancy in this pregnancy whilst receiving care by the OUHFT.\n* If intrapartum care takes place outside of the OUHFT.","60 Years",{"count":226,"type":22},56000,"Fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (Gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of fetal growth' (MBRRACE, 2015).\n\nTherefore, antenatal detection of growth restricted babies is vital in order to be able to monitor and decide the appropriate delivery timing.\n\nHowever, antenatal detection of SGA babies has been poor, varying greatly across trusts in England in those that calculate their rates (NHS England, 2016). Most trusts do not calculate their detection rates and rates are therefore unknown. It is estimated that routine NHS care detects only 1 in 4 growth restricted babies (Smith, 2015).\n\nOxford University Hospitals NHS Foundation Trust, in partnership with the Oxford Academic Health Science Network (AHSN) has introduced a clinical care pathway (the Oxford Growth Restriction Pathway (OxGRIP)) designed to increase the rates of detection of these at risk babies. The pathway is intended to increase the identification of babies who are at risk of stillbirth, in order to try to prevent this outcome, whilst making best usage of resources, and restricting inequitable practice and unnecessary obstetric intervention.\n\nIt has been developed with reference to a body of research, however, the individual parts of care provided have not been put together in a pathway in this manner before. Therefore it is important to examine whether the pathway meets its goals of improving outcomes for babies in a 'real world' setting.\n\nThe principles of the pathway are\n\n1. A universal routine scan at 36 weeks gestation.\n2. Additional growth scans at 28 and 32 weeks gestation based on a simplified assessment of risk factors and universal uterine artery Doppler at 20 weeks gestation.\n3. Assessment of further parameters other than estimated fetal weight associated with adverse perinatal outcome (eg growth velocity, umbilical artery Doppler and CPR).\n\nThe clinical data routinely collected as a result of the introduction of the pathway offers a valuable and unique resource in identifying and analysing in the effects of the pathway on its intended outcomes and also in investigating and analysing other maternal, fetal and neonatal complications and outcomes, establishing normal \u002F reference ranges for ultrasound values.",[30,193,229,230,231,104,232],"Fetal Growth Retardation","Small for Gestational Age","Fetal Growth Restriction","Intrauterine Growth Restriction","2026-01-27",{"date":235,"type":46},"2026-01-29",{"date":237,"type":46},"2017-09-01",{"date":239,"type":22},"2029-09-30",{"name":241,"class":53},"Oxford University Hospitals NHS Trust",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":95,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":63,"phases":253,"briefSummary":254,"conditions":255,"keywords":259,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":284},"100571679","phase-3-asymptomatic-bacteriuria-in-pregnancy-in-low--and-middle-income-countries-100571679","NCT06723392","Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries","Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries: A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research","ABLE","Inclusion Criteria:\n\nIndividuals who meet the following criteria are eligible for randomization:\n\n* Enrolled in GN MNHR\n* Established pregnancy ≥12 and ≤20 weeks GA by last menstrual period and\u002For clinical assessment and\u002For ultrasonography\n* Age: 18 years (or lower limit age eligible\\*) to 49 years\n\n  \\* Some sites will be able to include individuals giving birth regardless of age if they are considered an adult or an emancipated minor. However, other sites will require individuals to be at least 18 years of age. The investigators will adhere to local regulations.\n* Expressed understanding of study procedures and willingness to complete screening, randomization, study drug administration and follow-up\n* Able to provide informed consent\n* Presence of a single bacterial isolate (\\>105 colony forming unit (CFU)\u002FmL) in urine at enrollment\n* Intent to remain in study area for at least 42 days PP\n\nExclusion Criteria:\n\nIndividuals who meet any of the following criteria are not eligible for randomization:\n\n* Gestational age \\\u003C12 weeks or \\>20 weeks\n* Received treatment with any antibiotic within 14 days before screening visit\n* Current symptoms of UTI\n* History of allergy to nitrofurantoin\n* Pregnancy loss \u002F miscarriage prior to randomization\n* Currently taking magnesium-containing antacid\n* Any illness \u002F condition (e.g., anemia, diabetes, renal disease, pulmonary disease) requiring immediate medical care per site PI assessment\n* Enrollment in another trial that per the study MOP will impact this trial","49 Years",{"count":252,"type":22},1134,[66],"This study, Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries (ABLE), is designed as a 2-arm randomized controlled trial (RCT) focused on pregnant individuals and newborn infants. A positive outcome of this study will contribute to global progress toward WHO Sustainable Development Goal Target 3.2 \\[End preventable deaths of newborns and children under 5 years of age\\] by examining the potential impact of this practice to reduce the incidence of SVN\u002FSB and the lifelong health consequences associated with SVNs. In addition, the study will further explore the role and potential benefits of antibiotic treatment of AB in the pregnant individual. In total, 1,134 eligible participants, or approximately 162 per research site, will be randomized in the trial by the research teams in each of the seven international sites that, together with their United States of America (US) partners, participate in the Eunice Kennedy Shriver National Institute of Child Health and Human Development's (NICHD's) Global Network for Women's and Children's Health Research (GN).",[256,257,30,258],"Preterm Birth","Small for Gestational Age (SGA)","Bacteriuria (Asymptomatic) in Pregnancy",[260,261,262,263,264,265,266,267,268,269,270,271,272,273],"asymptomatic bacteriuria","small vulnerable newborn","preterm birth","small for gestational agea","still birth","SVN\u002FSB","oral nitrofurantoin monohydrate\u002Fmacrocrystals","Global Network","Bangladesh","India","Pakistan","Democratic Republic of Congo","Zambia","Guatemala","2026-01-20",{"date":276,"type":46},"2026-01-22",{"date":278,"type":46},"2025-12-08",{"date":280,"type":22},"2028-11",{"name":282,"class":283},"NICHD Global Network for Women's and Children's Health","NETWORK",7,{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":148,"maxAge":123,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":86},"100604078","placental-risk-assessment-to-customize-individualized-pregnancy-care-and-evaluation-100604078","NCT07144839","Placental Risk Assessment to CusTomize Individualized Pregnancy Care and Evaluation","Clinical Utility of a Predictive Model of Placental Insufficiency","PRACTICE","Inclusion Criteria:\n\n* Pregnant\n* Age 15 or older\n* No known major fetal anatomic or genetic abnormalities\n* Singleton gestation\n* Planning to deliver at Oregon Health \\& Science University\n* Prior to 22 weeks' gestation\n\nExclusion Criteria:\n\n* Decisional impairment\n* Multiple gestation\n* Known fetal growth restriction or major congenital anomaly\n* Inability to consent\n* Inability to attend study visits",{"count":294,"type":22},640,"This is a prospective observational study with the goal of developing and assessing a predictive model of placental insufficiency.",[30,297],"Placental Insufficiency","2025-12-15",{"date":300,"type":46},"2025-12-17",{"date":302,"type":46},"2025-09-18",{"date":304,"type":22},"2029-06",{"name":306,"class":53},"Oregon Health and Science University",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":95,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":316,"studyType":23,"phases":4,"briefSummary":317,"conditions":318,"keywords":323,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":340},"100586658","association-of-assisted-reproductive-technologies-parameters-with-the-perinatal-outcome-100586658","NCT06918236","Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome","Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome in Singleton and Multiple Pregnancies: A Multicenter Prospective Cohort Study","Inclusion Criteria\n\n* Singleton or multiple pregnancies\n* Live fetus between 11 weeks plus 0 days and 13 weeks plus 6 days of gestation\n\nExclusion Criteria\n\n* Known genetic anomalies diagnosed before or after birth\n* Major fetal defects diagnosed before or after birth, such as acrania, holoprosencephaly, megacystis, exomphalos, congenital heart defects",{"count":315,"type":22},12084,"9 Months","The goal of this prospective cohort study is to examine how different parameters of assisted reproductive technologies (ART) are associated with the perinatal outcome in individuals with singleton or multiple gestations. The main questions it aims to answer are:\n\nAre ART pregnancies associated with a higher risk of:\n\n* Small for gestational age neonates?\n* Fetal growth restriction, either early- or late-onset?\n* Development of preeclampsia?\n* Stillbirth (intrauterine fetal death after 22 weeks not due to known anomalies)?\n* Are certain ART parameters-such as the type of fertilization (e.g., IVF vs. ICSI), embryo stage at transfer, use of fresh vs. frozen embryos, or ovarian stimulation protocols-more strongly associated with adverse outcomes?\n\nAre ART pregnancies associated with placental and umbilical cord abnormalities, including:\n\n* Placenta previa?\n* Vasa previa?\n* Single umbilical artery?\n* Velamentous or marginal cord insertion?\n\nResearchers will compare outcomes between pregnancies conceived through ART and those conceived spontaneously.\n\nParticipants will:\n\n* Be individuals aged 18 or older undergoing routine first-trimester ultrasound between 11 and 14 weeks of gestation\n* Provide detailed medical, obstetric, and ART-related information\n* Undergo routine prenatal assessments, including ultrasound evaluations of fetal growth, Doppler studies, and placental characteristics\n* Have perinatal outcomes such as gestational age at birth, mode of delivery, birthweight, and complications systematically recorded\n\nStatistical models will be used to adjust for confounding factors such as maternal age, BMI, parity, and smoking.\n\nThe aim is to better understand how ART and specific ART parameters may influence maternal and neonatal health and to improve counseling and clinical care for people using fertility treatments.",[319,320,30,321,322,257],"Fetal Growth Restriction (FGR)","Preeclampsia","Placenta Previa","Vasa Previa",[324,320,35,325,326,327,328,257,329,330],"fetal growth restriction","placenta previa","vasa previa","Assisted reproductive techniques","ART","IVF","ICSI","2025-04-05",{"date":333,"type":46},"2025-04-09",{"date":335,"type":46},"2024-10-01",{"date":337,"type":22},"2028-12",{"name":339,"class":53},"Aristotle University Of Thessaloniki",6,{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":96,"minAge":4,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":86},"100432009","study-on-early-genetic-screening-and-precise-strategy-of-neonatal-critical-illness-100432009","NCT04905537","Study on Early Genetic Screening and Precise Strategy of Neonatal Critical Illness","Inclusion Criteria:\n\n* Postnatal age less than 100 days;\n* Perinatal death after 20 weeks of gestation (more than 500 g)\n* Can be retained biological samples for genetic screening;\n* Biological parent or guardian's informed consent.\n\nExclusion Criteria:\n\n* Reluctance of parents to use genetic sequencing data for subsequent research;\n* Parents under 18 years of age or incapacitated for decision-making;\n* subjects older than 100 days;\n* Perinatal death less than 20 weeks of gestation or weight less than 500 g;\n* Inherited metabolic diseases with chromosomal abnormalities;\n* Multiple pregnancies;\n* Lack of access to biological samples from which DNA can be extracted;\n* Failure to sign informed consent.","100 Days",{"count":349,"type":22},4000,"The researchers hope to establish an overall program of early genetic screening for neonatal critical illness in China, and to develop precise intervention strategies to assist clinical diagnosis and treatment of hereditary critical illness.",[352,353,354,30],"Genetic Screening","Hereditary Disease","Newborn","2025-02-19",{"date":357,"type":46},"2025-02-20",{"date":359,"type":46},"2021-01-01",{"date":361,"type":22},"2025-12",{"name":363,"class":53},"Children's Hospital of Fudan University",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":372,"targetDuration":4,"studyType":63,"phases":373,"briefSummary":374,"conditions":375,"keywords":379,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":215},"100537067","improving-intrapartum-care-for-saving-life-at-birth-in-ethiopia-through-partoma-approach-100537067","NCT06273007","Improving Intrapartum Care for Saving Life at Birth in Ethiopia Through PartoMa Approach","Introducing PartoMa Approach to Ethiopia for Improving Intrapartum Care and Maternal Survival: The Case of the Ethiopian Obstetric Surveillance System (PartoMa-Ethiopia)","PartoMa-Eth","Inclusion Criteria:\n\n* All women in labour delivering at the study site and their outcome, July - September 2023 and July -September 2025\n* All birth attendant at the study site in obstetrics and gynecology departments during the baseline and intervention period, July - September 2023 and July -September 2025\n\nExclusion Criteria:\n\n* NA",{"count":125,"type":22},[101],"Overall Objective\n\nTo introduce PartoMa approach (locally agreed and achievable intrapartum guidelines and a continual in-house training program) to Ethiopian context through continuous fetal heart rate (FHR) monitoring using MOYO device and co-creation of context specific intrapartum care guideline for improving decision making in intrapartum care in Eastern Ethiopia.\n\nInterventions\n\n1. Locally agreed and achievable intrapartum guidelines\n2. Low dose high frequency trainings (LDHF)\n3. Partograph Overall Design\n\nA quasi-experimental pre-post study (PartoMa study)\n\nSetting\n\nDepartment of Obstetrics and Gynaecology Haramaya Hospital and Hiwot Fana University Hospital, Ethiopia.\n\nPopulation\n\nLaboring women delivering at the study site from February 2023 to March 2025 and their offspring, as well as health providers. Women and their offspring will be enrolled at\u002Fafter onset of labour and followed until discharge.\n\nEndpoints\n\nThe primary endpoint is perinatal mortality. For further description and secondary outcomes, please see below.\n\nStudy Time\n\nData collection from June 2023 to May 2025.\n\nSpecific Objectives i. To assess FHR monitoring practice and use of obstetric guideline for decision making in Hiwot Fana University Hospital ii. To improve feto-maternal outcome through applying PartoMa approach in Hiwot Fana University Hospital.\n\niii. To determine the feasibility, acceptability and sustainability of low-dose high frequency trainings and PartoMa seminars in Hiwot Fana University Hospital.\n\niv. To document changes in pregnancy outcomes after the introduction of PartoMa approaches-seminars, low dose high frequency trainings, continuous FHR monitoring and tailored interventions-in Hiwot Fana University Hospital.\n\nSetting\n\nPartoMa Ethiopia will be implemented at Haramaya General Hospital and Hiwot Fana Comprehensive Specialized University Hospital, which are both busy maternity units in Eastern Ethiopia. Both are government hospitals with an annual delivery number of around 5,000.",[30,376,377,104,378],"Obstetric Complication","Maternal Death","Perinatal Morbidity",[380,381,382,383,384,385,386],"Obstetrics","perinatal","maternal","Intrapartum","Quality","PartoMa","LDHF","2024-02-15",{"date":389,"type":46},"2024-02-22",{"date":391,"type":46},"2023-06-01",{"date":393,"type":22},"2027-12-31",{"name":395,"class":53},"Haramaya Unversity"]